Crossmark

Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients

Crossref DOI link: https://doi.org/10.1186/s12920-021-01004-y

Published Online: 2021-06-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Song, Jin-Fang

Zhang, Jie

Zhang, Ming-Zhu

Ni, Jiang

Wang, Tao

Zhao, Yi-Qing

Khan, Naveed Ullah
Clinical Trials ^BETA

Clinical trials referenced in this document:

chictr13003536 at Chinese Clinical Trial Registry

Documents that mention this clinical trial

Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients
https://doi.org/10.1186/s12920-021-01004-y
License Information

Text and Data Mining valid from 2021-06-12

Version of Record valid from 2021-06-12
More Information

Article History

Received: 18 February 2021

Accepted: 1 June 2021

First Online: 12 June 2021

Declarations

:

: Manuscript reporting studies involving human participants, human data or human tissue are reported with approved statement on ethics approval and consent under registration ChiCTR-CCC-13003536.

: Not Applicable.

: The authors declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below